List of Excipients in Branded Drug FML FORTE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	FML FORTE	fluorometholone	11980-228	BENZALKONIUM CHLORIDE
Allergan Inc	FML FORTE	fluorometholone	11980-228	EDETATE DISODIUM
Allergan Inc	FML FORTE	fluorometholone	11980-228	POLYSORBATE 80

FML Forte Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

FML Forte is a legacy ophthalmic corticosteroid suspension containing fluorometholone acetate 0.25%. Its commercial opportunity is not primarily patent exclusivity. It is formulation execution: maintaining sterile, physically stable steroid particles while improving preservative tolerability, dose uniformity, container performance, and patient convenience. The strongest product concepts are preservative-free unit-dose suspension, low-irritation multidose packaging, and differentiated drop-delivery systems.

Important product facts

Attribute	FML Forte
Active ingredient	Fluorometholone acetate
Strength	0.25% ophthalmic suspension
Dosage form	Sterile topical ophthalmic suspension
Therapeutic class	Ophthalmic corticosteroid
Main use	Steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment
Reference-product commercial association	Allergan, now within AbbVie
Key formulation issue	Uniform redispersion and delivery of a poorly water-soluble corticosteroid
Primary competitive risk	Generic fluorometholone or fluorometholone acetate ophthalmic suspensions
Main commercial gap	Preservative exposure, bottle usability, and adherence rather than active-ingredient differentiation

The marketed formulation uses conventional ophthalmic suspension excipients, including a wetting or dispersing agent, viscosity-control polymer, buffering salts, tonicity agents, chelating agent, preservative, and purified water. The product label identifies polyvinyl alcohol, polysorbate 80, sodium chloride, phosphate buffers, edetate disodium, benzalkonium chloride, and water among the inactive ingredients.[1]

What excipients are used in FML Forte?

FML Forte uses excipients that support suspension stability, ocular tolerability, and multidose sterility.

Excipient function	FML Forte formulation role	Commercial significance
Polyvinyl alcohol	Viscosity control, wetting, lubrication, and suspension support	Affects drop size, residence time, and shake-redispersion behavior
Polysorbate 80	Wetting and dispersion of hydrophobic steroid particles	Can reduce aggregation but requires control of oxidation and peroxide impurities
Sodium chloride	Tonicity adjustment	Contributes to ocular comfort
Sodium phosphate salts	Buffering and pH control	Influences solubility, particle stability, and irritation
Edetate disodium	Chelation of trace metals	Can improve preservative performance and reduce metal-catalyzed degradation
Benzalkonium chloride	Multidose antimicrobial preservative	Creates an opportunity for preservative-free or lower-exposure products
Purified water	Vehicle	Requires sterile processing and tight microbial control

The exact excipient concentrations and manufacturing parameters are commercially important even when the ingredient list is public. Particle-size distribution, polymorphic form, milling conditions, wetting sequence, mixing energy, hold time, fill volume, and container closure can materially affect delivered dose.

How does the FML Forte suspension work from an excipient perspective?

Fluorometholone acetate has limited aqueous solubility. FML Forte therefore relies on a dispersed solid phase rather than a fully dissolved drug solution. The formulation must deliver a consistent amount of steroid after shaking and during the usable life of the bottle.

Three performance attributes control product quality:

1. Redispersibility. Sediment must redisperse rapidly with ordinary patient shaking.
2. Dose uniformity. The first, middle, and final doses should contain comparable drug concentrations.
3. Ocular tolerability. The vehicle must avoid excessive stinging, blurred vision, residue, or preservative-related surface damage.

Polyvinyl alcohol increases continuous-phase viscosity and can slow sedimentation. Polysorbate 80 improves particle wetting and limits agglomeration. The formulation cannot simply maximize viscosity or surfactant concentration. Excess viscosity can reduce drop delivery and increase blurred vision, while excess surfactant can increase irritation or destabilize the suspension.

What formulation patents protect FML Forte?

FML Forte is a legacy product, and its principal commercial protection does not appear to depend on a current, high-value formulation patent estate. The reference product’s relevant formulation know-how is more likely to reside in manufacturing controls, particle engineering, sterile processing, and container-closure specifications than in an active Orange Book patent barrier.

The FDA Orange Book is the primary source for patents and regulatory exclusivities associated with approved drug products.[2] For a legacy topical ophthalmic product such as FML Forte, a competitor should separate four categories of protection:

Protection category	FML Forte relevance
Active-ingredient patent	Likely expired for this mature corticosteroid
Formulation patent	Potentially limited or expired; must be confirmed against current Orange Book data
Method-of-use patent	Low expected barrier for the broad legacy anti-inflammatory indication
Manufacturing trade secret	Potentially important, especially for particle-size control and sterile suspension processing

A patent search should cover fluorometholone acetate particle size, ophthalmic suspensions, preservative-free packaging, dropper systems, and manufacturing methods. A competitor should also review patent-family continuation history, terminal disclaimers, reissue activity, and patent-term adjustment before relying on a freedom-to-operate conclusion.

When does FML Forte lose exclusivity?

FML Forte is a mature ophthalmic corticosteroid product. Its original small-molecule and regulatory exclusivity periods have expired or no longer represent the principal commercial barrier. Generic competition is therefore possible through the abbreviated new drug application pathway, subject to FDA approval requirements.

The relevant commercial timeline is:

Milestone	Strategic implication
Original NDA approval	Established safety, efficacy, and reference-product status
Small-molecule exclusivity expiration	Removed the principal FDA exclusivity barrier
Patent expiry or absence of listed patents	Enables ANDA filing without a patent-based launch delay
Generic approvals	Creates price pressure and pharmacy substitution
Ongoing reference-product sales	Supports branded or authorized-generic lifecycle strategies

The precise current Orange Book status should control any launch decision. Product-level assumptions based only on the age of FML Forte are not sufficient because patents can be listed, delisted, or challenged over time.

What FDA regulatory pathway applies to FML Forte competitors?

A conventional generic competitor would generally pursue an ANDA referencing the approved fluorometholone acetate ophthalmic suspension. The central regulatory issue is pharmaceutical equivalence and bioequivalence for a complex topical suspension.

The applicant would typically need to control:

• Active ingredient identity and strength
• Particle-size distribution
• Solid-state characteristics
• pH and osmolality
• Viscosity and rheology
• Redispersibility
• Sedimentation rate
• Appearance and resuspendability
• Delivered volume and drop size
• Microbial limits and sterility
• Preservative content and effectiveness
• Container-closure integrity
• Stability throughout the proposed shelf life

FDA guidance for ophthalmic products treats suspension properties as clinically relevant because the drug is administered directly to the eye and dose delivery depends on physical behavior, not only assay results.[3]

A product with a materially different excipient system may require more extensive bridging work. The regulatory burden increases when the applicant changes preservative technology, uses a novel polymer, adopts a nonstandard container, or claims a clinically meaningful improvement.

What excipient strategies could improve FML Forte?

Preservative-free unit-dose suspension

The clearest opportunity is a single-use, preservative-free presentation. Benzalkonium chloride is effective in multidose ophthalmic products but is associated with ocular-surface tolerability concerns, particularly with repeated use or pre-existing surface disease.[4]

A preservative-free unit-dose product could target:

• Patients requiring frequent dosing
• Dry-eye or ocular-surface disease populations
• Postoperative inflammation
• Patients with known preservative sensitivity
• Ophthalmology practices seeking lower-exposure steroid options

The principal challenges are unit-dose fill cost, packaging waste, dose uniformity across ampoules, and maintaining suspension homogeneity during filling.

Preservative-reduced multidose system

A multidose bottle using a one-way valve, antimicrobial container, or mechanically protected dispensing system could reduce or eliminate benzalkonium chloride. The commercial value would be higher than a simple generic if the package improves tolerability without materially increasing manufacturing cost.

The product would need robust container-closure integrity, in-use microbial protection, and dose-delivery validation. The container becomes part of the product’s regulatory control strategy.

Alternative wetting systems

Polysorbate 80 is established but can present oxidation, peroxide, and compatibility risks. A development program could evaluate poloxamers, tyloxapol, phospholipid-based systems, or combinations of nonionic surfactants.

The selection criteria should include:

• Particle wetting
• Redispersibility after storage
• Surfactant degradation
• Ocular irritation
• Extractables and leachables
• Compatibility with the bottle and stopper
• Lack of excessive foaming during manufacture

A new wetting system is commercially useful only if it improves a measurable product attribute. Substitution alone is unlikely to support premium pricing.

Polymer optimization

Polyvinyl alcohol is functional but can affect viscosity, drop size, and transient visual blur. Alternative viscosity modifiers, including selected cellulose derivatives or carbomer systems, could improve residence time or reduce settling.

The risk is that a higher-viscosity system may produce an uncomfortably large drop, alter drainage through the nasolacrimal system, or complicate aseptic filling. The target should be a narrow rheological window rather than maximum viscosity.

Improved particle engineering

Micronization, controlled crystallization, and narrower particle-size distributions can improve suspension uniformity and reduce grittiness. Particle engineering may also reduce the amount of surfactant needed.

The key controls include:

• D10, D50, and D90 particle size
• Crystal morphology
• Polymorphic form
• Surface energy
• Agglomerate content
• Sedimentation profile
• Redispersibility after freeze-thaw and accelerated storage

Particle engineering is one of the strongest areas for manufacturing know-how because the formulation composition alone does not disclose the complete process.

What commercial opportunities exist for FML Forte alternatives?

Generic price competition

The lowest-cost opportunity is an ANDA product that closely matches the reference formulation and packaging. Its success depends on manufacturing scale, wholesaler access, payer substitution, and supply reliability.

A generic entrant may compete through:

• Lower acquisition cost
• Reliable availability
• Contract pharmacy distribution
• Authorized-generic arrangements
• Hospital and clinic contracts
• Multiple bottle sizes

This strategy has limited pricing power and is vulnerable to rapid erosion once several suppliers enter.

Premium preservative-free product

A preservative-free FML Forte alternative can target a higher-value segment. It would compete on tolerability and patient suitability rather than price alone.

Potential commercial channels include:

• Ophthalmology specialists
• Ambulatory surgery centers
• Hospital formularies
• Specialty pharmacies
• Dermatology and ocular-surface practices
• Prescriber-directed formulations for chronic or recurrent inflammation

The product must demonstrate practical advantages such as easier dosing, reduced stinging, or improved adherence. A preservative-free label without a clear use-case may not justify a premium.

Device-enabled delivery

A controlled-drop bottle could reduce waste and improve dosing consistency. Features may include smaller drop volume, tactile feedback, one-handed operation, and non-return valve protection.

For ophthalmic suspensions, a device can create a defensible commercial position if it improves:

• Dose accuracy
• Ease of shaking
• Ability to administer the product without touching the eye
• Residual volume
• Stability after opening

The patent estate would likely focus on the container and delivery system rather than the steroid molecule.

Combination and co-pack products

A co-pack combining an ophthalmic steroid with an antibiotic or lubricating product could target postoperative care, but combination development introduces regulatory and clinical complexity. The product must avoid inappropriate steroid use in infections and must establish the clinical rationale for the combined regimen.

A lower-risk option is a co-packaged regimen sold with separate products, provided labeling and promotional practices comply with FDA requirements.

Which companies are challenging or competing with FML Forte?

Competition comes from three groups:

1. Generic fluorometholone suppliers. These companies compete directly on the same active ingredient and dosage form.
2. Alternative ophthalmic corticosteroid brands. Loteprednol etabonate, prednisolone acetate, dexamethasone, and difluprednate compete for steroid-responsive ocular inflammation.
3. Preservative-free and device-enabled products. These products compete on tolerability, delivery, and postoperative workflow.

Product category	Competitive advantage	Limitation
Fluorometholone generic	Low price and therapeutic familiarity	Limited differentiation
Prednisolone acetate suspension	Strong physician familiarity and broad use	Greater concern about intraocular pressure and formulation variability
Loteprednol etabonate	Ester-steroid positioning and branded differentiation	Higher price
Difluprednate	Potency and dosing convenience	Higher cost and safety monitoring
Preservative-free steroid	Ocular-surface positioning	Higher packaging and manufacturing cost

FML Forte’s opportunity is strongest where clinicians value a relatively established corticosteroid with a lower-cost profile but need better tolerability or delivery.

What patent litigation and Paragraph IV risks exist?

A generic applicant must review Orange Book patents and may submit a Paragraph IV certification if it believes a listed patent is invalid, unenforceable, or will not be infringed. If the patent holder files suit within the statutory period, the FDA may face a 30-month stay of approval under the Hatch-Waxman framework.[5]

For a mature FML Forte product, the expected risk profile is:

Risk	Assessment
Active-ingredient patent litigation	Low for a legacy fluorometholone product
Broad method-of-use litigation	Low to moderate, depending on listed claims
Formulation patent challenge	Product-specific
Device or packaging litigation	Increasingly relevant for differentiated products
Paragraph IV settlement risk	Relevant only if active Orange Book patents are listed
Biosimilar risk	Not applicable because FML Forte is a small-molecule drug

No biosimilar pathway applies. The principal legal issues are ANDA patent certifications, formulation claims, device patents, and trade-secret protection for manufacturing processes.

How strong is the FML Forte patent estate?

The patent estate is likely weak as a barrier to ordinary generic entry but stronger at the process and device level.

Estate component	Relative strength
Fluorometholone acetate composition	Low due to product maturity
Basic ophthalmic suspension	Low unless narrow claims remain enforceable
Specific excipient ratios	Moderate if claims are novel and technically supported
Particle-size and crystal-form claims	Moderate to strong if narrowly drafted
Preservative-free presentation	Moderate, depending on packaging claims
Multidose dispensing device	Moderate to strong for a differentiated device
Manufacturing process	Potentially strong as trade secret
Clinical method of use	Generally limited for broad anti-inflammatory use

Commercial diligence should focus on whether any active claims cover the exact strength, suspension architecture, container, or manufacturing sequence. Public ingredient disclosure does not eliminate process-level protection.

What manufacturing and IP barriers matter most?

The main barrier is sterile suspension manufacturing at commercial scale. Critical operations include:

• Sterile micronization or sterilization strategy
• Controlled particle wetting
• Homogeneous bulk suspension preparation
• Prevention of sediment compaction
• Aseptic filling
• Accurate fill-weight control
• Bottle and tip compatibility
• Preservative effectiveness
• In-use stability after repeated opening

A manufacturer with weak suspension-process capability may meet assay and sterility specifications but fail dose uniformity, redispersibility, or patient-use testing. Those failures can delay approval and create post-launch complaints.

Key Takeaways

• FML Forte is a mature fluorometholone acetate 0.25% ophthalmic suspension.
• Its commercial value is concentrated in formulation reliability, not apparent molecule-level exclusivity.
• The core excipient system supports wetting, viscosity, buffering, tonicity, chelation, and multidose preservation.
• A preservative-free unit-dose suspension is the clearest differentiated opportunity.
• A low-preservative multidose bottle and controlled-drop device are commercially credible follow-on strategies.
• Generic entry risk is high if no active Orange Book patent blocks approval.
• Biosimilar risk does not apply.
• The most defensible technical assets are particle engineering, suspension-processing controls, container systems, and manufacturing know-how.
• A basic generic strategy offers volume but limited margin. Premium positioning requires demonstrable tolerability, adherence, or delivery advantages.

FAQs

Is FML Forte a solution or a suspension?

FML Forte is a sterile ophthalmic suspension. The corticosteroid is dispersed as solid particles and must be shaken before use.

Does FML Forte contain benzalkonium chloride?

The marketed formulation is labeled with benzalkonium chloride as a preservative. This creates an opportunity for preservative-free unit-dose or preservative-reduced multidose alternatives.[1]

Is a preservative-free FML Forte generic commercially attractive?

Yes, particularly for ocular-surface disease, frequent dosing, and postoperative patients. The opportunity depends on achieving dose uniformity and acceptable unit-dose manufacturing costs.

Can a company obtain a patent on a new FML Forte formulation?

Potentially. Patentability would depend on novelty, nonobviousness, written description, enablement, and claim scope. Stronger candidates include defined particle-size distributions, improved suspension stability, preservative-free packaging, and specialized delivery devices.

Does FML Forte have biosimilar competition?

No. FML Forte contains a small-molecule corticosteroid, so competitors use generic-drug pathways rather than the biosimilar pathway.

References

1. DailyMed. (n.d.). FML Forte: Fluorometholone acetate ophthalmic suspension, 0.25% prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. U.S. Food and Drug Administration. (2023). Ophthalmic drug products for topical ophthalmic administration: Product quality guidance. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2014). Evaluation of drug products used in ophthalmic surgery and procedures. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. U.S. Department of Health and Human Services.